Novel approaches in advancing the treatment of epithelial ovarian cancer: The role of angiogenesis inhibition

Journal of Clinical Oncology

Volumn 25, Issue 20, 2007, Pages 2894-2901

  Martin, Lainie ^a   Schilder, Russell ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVE 0005; BEVACIZUMAB; CARBOPLATIN; DASATINIB; DOCETAXEL; DOXORUBICIN; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYBRID PROTEIN; IRINOTECAN; MONOCLONAL ANTIBODY; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; PACLITAXEL; PERTUZUMAB; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB; VOLOCIXIMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ANGIOGENESIS; CENTRAL NERVOUS SYSTEM ISCHEMIA; CLINICAL TRIAL; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM PERFORATION; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HYPERTENSION; INTESTINE PERFORATION; ISCHEMIA; KIDNEY CARCINOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVARY CARCINOMA; OVARY FUNCTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOSIS; BIOLOGICAL MODEL; CARCINOMA; FEMALE; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); ONCOLOGY; OVARY; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; FEMALE; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; OVARY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34447499062     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.1088     Document Type: Review

References (86)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
3. Darcy KM, Schilder RJ: Relevant molecular markers and targets. Gynecol Oncol 103:S6-S13, 2006 (suppl 1)
4. Adjei AA, Hidalgo M: Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol 23:5386-5403, 2005
5. Agarwal R, Linch M, Kaye SB: Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 32):875-886, 2006
6. Bhoola SM, Alvarez RD: Novel therapies for recurrent ovarian cancer management. Expert Rev Anticancer Ther 4:437-448, 2004
7. See HT, Kavanagh JJ: Novel agents in epithelial ovarian cancer. Cancer Invest 22:29-44, 2004 (suppl 2)
8. Martin L, Schilder RJ: Novel non-cytotoxic therapy in ovarian cancer: Current status and future prospects. J Natl Compr Canc Netw 4:955-966, 2006
9. Burger RA, Sill M, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol 23:457s, 2005 (suppl; abstr 5009)
10. Garcia AA, Oza AM, Hirte H, et al: Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. J Clin Oncol 23:455s, 2005 (suppl; abstr 5000)
11. Cohn DE, Valmadre S, Resnick KE, et al: Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 102:134-139, 2006
12. Patan S, Munn LL, Jain RK: Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: A Novel mechanism of tumor angiogenesis. Microvasc Res 51:260-272, 1996
13. Asahara T, Murohara T, Sullivan A, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-966, 1997
14. Maniotis AJ, Folberg R, Hess A, et al: Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol 155:739-752, 1999
15. Dome B, Timar J, Paku S: A novel concept of glomeruloid body formation in experimental cerebral metastases. J Neuropathol Exp Neurol 62:655-661, 2003
16. Holash J, Maisonpierre PC, Compton D, et al: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998, 1999
17. Ausprunk DH, Folkman J: Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14:53-65, 1977
18. Goede V, Schmidt T, Kimmina S, et al: Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 78:1385-1394, 1998
19. Ramakrishnan S, Subramanian I, Yokoyama Y, et al: Angiogenesis in normal and neoplastic ovaries Angiogenesis 8:169-182, 2005
20. Olson TA, Mohanraj D, Carson LF, et al: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54:276-280, 1994
21. Yeo K-T, Wang HH, Nagy JA, et al: Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 53:2912-2918, 1993
22. Hata K, Nakayama K, Fujiwaki R, et al: Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer. Gynecol Oncol 93:215-222, 2004
23. Heldin C: Structural and functional studies on platelet-derived growth factor. EMBO J 11:4251-4259, 1992
24. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003
25. Soker S, Fidder H, Neufeld G, et al: Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF via its exon 7-encoded domain. J Biol Chem 271:5761-5767, 1996
26. Soker S, Takashima S, Miao HQ, et al: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735-745, 1998
27. Kawakami T, Tokunaga T, Hatanaka H, et al: Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer 95:2196-2201, 2002
28. Li M, Yang H, Chai H, et al: Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer 101:2341-2350, 2004
29. Stephenson JM, Banerjee S, Saxena NK, et al: Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: A possible marker for the progression of breast cancer. Int J Cancer 101:409-414, 2002
30. Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 7:987-989, 2001
31. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
32. Osada R, Horiuchi A, Kikuchi N, et al: Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: Increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 37:1414-1425, 2006
33. Tong RT, Boucher Y, Kozin SV, et al: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736, 2004
34. Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563, 2004
35. Giantonio BJ, Catalano PJ, Meropol NJ, et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23:1s, 2005 (suppl; abstr 2)
36. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
37. Sandler AB, Gray R, Brahmer J, et al: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 23:2s, 2005 (suppl; LBA4)
38. Cannistra SA, Matulonis U, Penson R, et al: Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol 24:257s, 2006 (suppl; abstr 5006)
39. Hu L, Hofmann J, Jaffe RB: Phosphatidylinostol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res 11:8208-8212, 2005
40. Verheul HMW, Hoekman K, Jorna AS, et al: Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation. Oncologist 5:45-50, 2000
41. Zebrowski BK, Liu W, Ramirez K, et al: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6:373-378, 1999
42. Senger DR, Galli SJ, Dvorak AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983
43. Wright JD, Alvarezsecord A, Numnum TM, et al: A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer. J Clin Oncol 24:18S, 2006 (suppl; abstr 5019)
44. Wild R, Dings RP, Subramanian I, et al: Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer 110:343-351, 2004
45. Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J Clin Oncol 24:148s, 2006 (suppl; abstr 3510)
46. Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712, 2005
47. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005
48. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 1045-1047, 2000
49. Browder T, Butterfield CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
50. Friberg G, Oza AM, Morgan RJ, et al: Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: Preliminary results of a multi-center phase II trial. J Clin Oncol 24:260s, 2006 (suppl; abstr 5018)
51. Byrne AT, Ross L, Holash J, et al: Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9:5721-5728, 2003
52. Dupont J, Schwartz L, Koutcher J, et al: Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. J Clin Oncol 22:14S, 2004 (suppl; abstr 3009)
53. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000
54. O'Farrell AM, Abrams TJ, Yuen HA, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597-3605, 2003
55. Rosen L, Mulay M, Long J, et al: Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc Am Soc Clin Oncol 22:191, 2003 (abstr 765)
56. Rosen L, Kurzrock R, Jackson E, et al: Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors. J Clin Oncol 23:195s, 2005 (suppl; abstr 3013)
57. Gao N, Flynn DC, Zhang Z, et al: G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 287:C281-C291, 2004
58. Altomare DA, Wang HQ, Skele KL, et al: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23:5853-5857, 2004
59. Testa JR, Tsichlis PN: AKT signaling in normal and malignant cells. Oncogene 24:7391-7393, 2005
60. Hudson CC, Liu M, Chiang GG, et al: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004-7014, 2002
61. Maxwell PH, Wiesener MS, Chang GW, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275, 1999
62. Shahin MS, Hughes JH, Sood AK, et al: The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89:2006-2017, 2000
63. Rapisarda A, Uranchimeg B, Sordet O, et al: Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64:1475-1482, 2004
64. Wan X, Shen N, Mendoza A, et al: CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 8:394-401, 2006
65. Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918, 2004
66. Yokogami K, Wakisaka S, Avruch J, Reeves SA: Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 10:47-50, 2000
67. Yoshiji H, Kuriyama S, Ways DK, et al: Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59:4413-4418, 1999
68. Carducci MA, Musib L, Kies MS, et al: Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24:4092-4099, 2006
69. Gross ME, Shazer RL, Agus DB: Targeting the HER-kinase axis in cancer. Semin Oncol 31:9-20, 2004 (suppl)
70. Jorissen RN, Walker F, Pouliot N, et al: Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 284:31-53, 2003
71. Campiglio M, Ali S, Knyazev PG, et al: Characteristics of EGFR family-mediated HRG signals in human ovarian cancer. J Cell Biochem 73:522-532, 1999
72. Laughner E, Taghavi P, Chiles K, et al: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004, 2001
73. Wen XF, Yang G, Mao W, et al: HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: Implications for HER2-targeted antibody therapy. Oncogene 25:6986-6996, 2006
74. Bookman MA, Darcy KM, Clarke-Pearson D, et al: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283-290, 2003
75. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
76. Gordon MS, Matei D, Aghajanian C, et al: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: Potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24:4324-4332, 2006
77. Bartlett JM, Langdon SP, Simpson BJ, et al: The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 73:301-306, 1996
78. Fischer-Colbrie J, Witt A, Heinzl H, et al: EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients. Anticancer Res 17:613-619, 1997
79. Schilder RJ, Sill MW, Chen X, et al: Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecologic Oncology Group Study. Clin Cancer Res 11:5539-5548, 2005
80. Pore N, Liu S, Haas-Kogan DA, et al: PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 63:236-241, 2003
81. Maity A, Pore N, Lee J, et al: Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60:5879-5886, 2000
82. Viloria-Petit A, Crombet T, Jothy S, et al: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61:5090-5101, 2001
83. Beeram M, Patnaik A, Rowinsky EK: Raf: A strategic target for therapeutic development against cancer. J Clin Oncol 23:6771-6790, 2005
84. Welch S, Hirte H, Schilder RJ, et al: Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial. J Clin Oncol 24:276s, 2006 (suppl; abstr 5084)
85. Ramakrishnan V, Bhaskar V, Law DA, et al: Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol 5:273-286, 2006
86. Serini G, Valdembri D, Bussolino F: Integrins and angiogenesis: A sticky business. Exp Cell Res 312:651-658, 2006